Immuron (IMRN) Total Non-Current Liabilities (2017 - 2025)
Immuron (IMRN) recorded quarterly Total Non-Current Liabilities of $945.77 in Q3 2025, down 98.44% quarter-over-quarter from $60570.3 in Q2 2025, and down 33.18% on a YoY basis from $1415.5 in Q3 2024.
Immuron (IMRN) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
Immuron's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $945.77 for Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 33.18% year-over-year to $945.77; the TTM figure through Sep 2025 stood at $945.77 (down 33.18% YoY), while the FY2025 annual figure was $945.77, down 33.18% from the prior year.
- Total Non-Current Liabilities was $945.77 for Q3 2025 at Immuron, down from $60570.3 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $125667.1 in Q2 2022 to a low of $860.99 in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $60271.1 across 5 years, with a median of $63476.0 in 2024.
- The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities jumped 8019.92% in 2021, then tumbled 99.25% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $26496.1 in 2021, then jumped by 335.05% to $115272.5 in 2022, then sank by 99.25% to $860.99 in 2023, then jumped by 7609.97% to $66381.8 in 2024, then plunged by 98.58% to $945.77 in 2025.
- The last three Total Non-Current Liabilities figures came in at $945.77 (Q3 2025), $60570.3 (Q2 2025), and $66381.8 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | 945.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 945.77 |
| Jun 30, 2025 | 60,570.25 |
| Dec 31, 2024 | 66,381.83 |
| Sep 9, 2024 | 1,415.46 |
| Jun 30, 2024 | 93,282.28 |
| Dec 31, 2023 | 860.99 |
| Sep 28, 2023 | 99,768.61 |
| Aug 30, 2023 | 1,522.07 |
| Jun 30, 2023 | 101,729.14 |
| Dec 31, 2022 | 115,272.50 |
| Aug 31, 2022 | 122,009.86 |
| Jun 30, 2022 | 125,667.13 |
| Dec 31, 2021 | 26,496.13 |
| Jun 30, 2021 | 27,872.92 |
| Dec 31, 2020 | 326.31 |
| Sep 1, 2020 | 41,839.00 |
| Jun 30, 2020 | 27,422.14 |
| Dec 31, 2019 | 418.39 |
| Jun 30, 2019 | 10,493.07 |
| Dec 31, 2017 | 1.83 Mn |